The global Graft Versus Host Disease Treatment Market sales is expected to reach US$ 5,655.37 million by 2032, with an 8.3% compound annual growth rate (CAGR). Because of the increased use of corticosteroids and combination medications to treat Graft Versus Host Disease in hematopoietic cell transplant (HCT) patient.